Please sign in to follow a disease.
A pill that mimics the body's oxygen sensor may free MDS patients from frequent blood transfusions
NCT ID NCT07722988
First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether roxadustat, an oral drug that stimulates red blood cell production, can help people with myelodysplastic syndromes (MDS) who need frequent blood transfusions. Participants with very low, low, or intermediate risk MDS and a high transfusion burden will receive either roxadustat or a placebo. The main goal is to see if the drug allows them to go without transfusions for at least 56 consecutive days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- roxadustat (FG-4592), an oral drug that stimulates red blood cell production
- What this could lead to
- If successful, roxadustat could offer a new treatment option to reduce or eliminate the need for frequent blood transfusions in people with MDS-related anemia.
- What could go wrong
- This is an early-phase 3 trial, and the drug may not prove effective or safe in this specific patient group. Potential risks include side effects common to drugs that boost red blood cell production, such as blood clots or high blood pressure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Drug combo aims to break anemia cycle in MDS patients
- Gene mapping of childhood blood cancers could unlock personalized treatments
- Epigenetic drugs aim to stop cancer return after transplant in kids
- Triple therapy aims to overcome antibody barrier in Half-Matched stem cell transplants
- Can a website ease the emotional toll of stem cell transplants?
- Combination therapy aims to boost blood cells in Hard-to-Treat MDS